Back to Search Start Over

Osmotic demyelination syndrome improving after immune-modulating treatment: Case report and literature review

Authors :
Georgios M. Hadjigeorgiou
Linos Hadjihannas
Stefania Kalampokini
Giorgos Parpas
Artemis Kyrri
Artemios Artemiadis
Panagiotis Zis
Source :
Clinical Neurology and Neurosurgery. 208:106811
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Background Osmotic demyelination syndrome (ODS), which embraces central pontine and extrapontine myelinolysis, is an uncommon neurological disorder that occurs due to plasma osmotic changes. Case presentation We present the case of a 55-year-old man, who presented with severe hyponatremia due to repeated vomiting, antidepressant treatment and consumption of large amounts of water. Fifteen days after sodium correction, the patient showed fluctuation of vigilance, dysarthria and dysphagia, tremor, cogwheel rigidity, bilateral facial palsy, ophthalmoplegia and tetraparesis. A brain MRI scan revealed extrapontine and later on pontine myelinolysis. He received intravenous steroids and subsequently immunoglobulin. His status began to improve gradually after completion of immunoglobulin and at three month-follow-up had no neurological deficit. Literature review A comprehensive literature search of all reported ODS cases that received immunoglobulin, steroids or plasmapheresis was conducted in the electronic databases PubMed and Web of science. Conclusions Improvement was seen in most cases that received immunoglobulin either during treatment or in the first days after treatment. With regard to steroids, although most cases reported improvement in the following months their effect on the outcome is unclear. Most cases treated with plasmapheresis reported favorable outcome at variable follow-up time. Immunoglobulin and steroids have immunomodulatory effects, which could contribute to promotion of myelin repair in ODS. Plasmapheresis has effects on the immune system beyond removing myelinotoxins from the circulation. More evidence is required to support their use in ODS. However, in view of the disease severity, these therapeutic choices should be considered in the clinical management of ODS.

Details

ISSN :
03038467
Volume :
208
Database :
OpenAIRE
Journal :
Clinical Neurology and Neurosurgery
Accession number :
edsair.doi.dedup.....f33b445db05a2d9e89f4c46ff941bca1
Full Text :
https://doi.org/10.1016/j.clineuro.2021.106811